Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Leerink Partners Reiterates Outperform Rating on Repligen (RGEN)
March 4, 2025 9:50 AM ESTLeerink Partners analyst Puneet Souda reiterated an Outperform rating and $200.00 price target on Repligen (NASDAQ: RGEN)
The analyst comments "Bottom Line: This morning, RGEN (OP) announced the acquisition of MASS's (MP) bioprocessing desktop portfolio including REBEL, MAVERICK/MAVEN, and ZipChip (overall ~450 total... More
